NovoCure (NVCR) Liabilities and Shareholders Equity (2014 - 2026)

NovoCure's Liabilities and Shareholders Equity history runs 13 years deep, the most recent figure standing at $787.9 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 36.91% year-over-year to $787.9 million; the TTM figure through Mar 2026 stood at $4.2 billion (down 14.71% YoY), while the FY2025 annual figure was $804.3 million, down 35.18% from the prior year.
• Liabilities and Shareholders Equity came in at $787.9 million for Q1 2026 at NovoCure, down from $804.3 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q3 2025 to a low of $787.9 million in Q1 2026.
• A 5-year average of $1.1 billion and a median of $1.2 billion in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity climbed 11.39% in 2025 and plunged 36.91% in 2026, its largest moves.
• NovoCure's Liabilities and Shareholders Equity stood at $1.2 billion in 2022, then fell by 3.82% to $1.1 billion in 2023, then rose by 8.26% to $1.2 billion in 2024, then sank by 35.18% to $804.3 million in 2025, then fell by 2.04% to $787.9 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $787.9 million, $804.3 million, and $1.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison